Dalfopristin+Quinupristin

Dalfopristin+Quinupristin Chemische Eigenschaften,Einsatz,Produktion Methoden

• Clinical Use

  A drug combination of the streptogramins, quinupristin and dalfopristin was approved for IV use in the treatment of infections caused by vancomycin-resistant Enterococcus faeci um bacteremia as well as skin/skin structure infections caused by MRSA and methicillin-sensitive Streptococcus pyogenes. Certain strains of E. faecium are resistant to essentially all other antibiotics, including vancomycin. The streptogramin type A compound dalfopristin binds to the 50S ribosomal subparticle, resulting in a conformational change in the substrate. It appears that dalfopristin binding creates a high-affinity binding site for quinupristin, accounting for the synergy.

Dalfopristin+Quinupristin Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global(2)Suppliers